MC
REGN icon

Maverick Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Maverick Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,758
Closed -$1.54M – 520
2023
Q4 		$1.54M Buy
+1,758
New +$1.45M 0.03% 97
2021
Q4 		– Sell
-490
Closed -$297K – 571
2021
Q3 		$297K Buy
+490
New +$304K ﹤0.01% 496
2020
Q4 		– Sell
-588
Closed -$329K – 762
2020
Q3 		$329K Buy
+588
New +$357K 0.01% 452

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Maverick Capital's REGN Position: Q1 2024 in Review

Maverick Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 1,758 shares — an estimated $1.54M sold.

Maverick Capital first reported a position in REGN in Q3 2020 and held it in 3 quarters. The position peaked at $1.54M in Q4 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Maverick Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Maverick Capital sold 1,758 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $1.54M.
  • Maverick Capital first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Maverick Capital's Regeneron Pharmaceuticals position peaked at $1.54M in Q4 2023.
  • 1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.